For the Inventor, By the Inventor

Enter assignee name

Shanghai, China

Hua Medicine (shanghai) Ltd.

USPTO Granted Patents = 13

Forward Citations = 5

Loading Chart...

Loading Chart...

15 inventors (with patents filed for the assignee):

Li Chen (13 out of 114 patents)

Yongguo Li (7 out of 8 patents)

Gaosen Wang (6 out of 6 patents)

4. Huisheng Gao (4 out of 4 patents)

5. Shuang Ren (3 out of 3 patents)

6. Jin She (2 out of 11 patents)

7. Jiayi Zhang (2 out of 2 patents)

8. Chengde Wu (1 out of 29 patents)

9. Xiaowei Jin (1 out of 1 patent)

10. Yuejiao Duan (1 out of 1 patent)

11. Xiangle Jin (1 out of 7 patents)

12. Yaohui Wang (1 out of 7 patents)

13. Guanghua Lv (1 out of 2 patents)

14. Chengfeng Jiao (1 out of 1 patent)

15. Fuxing Tang (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 12318366 - Pharmaceutical combination and composition, and combination preparation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof (2025-06-03),

2. 12064416 - Pharmaceutical combination containing glucose kinase activator and PPAR receptor activator, composition, compound preparation method for same, and uses thereof (2024-08-20),

3. 12054477 - Prodrug of pyrrolidone derivatives as glucokinase activator (2024-08-06),

4. 11992477 - Pharmaceutical combination, composition, and combination preparation comprising glucokinase activator and SGLT-2 inhibitor and preparation methods and uses thereof (2024-05-28),

5. 11963947 - Pharmaceutical combination, composition and compound preparation comprising glucokinase activator and DPP-IV inhibitor, and preparation method and use thereof (2024-04-23),

6. 11872221 - Treating untreated or treatment-resistant diabetes with glucokinase activator (2024-01-16),

7. 11857536 - Glucokinase activator for treating diabetes with renal impairment (2024-01-02),

8. 11813274 - Treating untreated or treatment-resistant diabetes with glucokinase activator and sodium-glucose cotransporter-2 inhibitor (2023-11-14),

9. 11666556 - Pharmaceutical combination, composition and compound preparation containing glucokinase activator and K-ATP channel blocker, preparation method therefor and use thereof (2023-06-06),

10. 11266630 - Oral preparation of glucokinase activator and preparation method therefor (2022-03-08),

11. 10941132 - Pyrazole derivatives (2021-03-09),

12. 10669255 - Pyrrole derivatives (2020-06-02),

13. 10328054 - Substituted pyrrolidines as mGluR5 antagonists (2019-06-25),

Hua Medicine (Shanghai) Ltd. is a clinical-stage biopharmaceutical company developing a portfolio of novel, innovative therapies for the treatment of diabetes and CNS disorders. Their lead product is dorzagliatin, a first-in-class, glucokinase activator for the treatment of type 2 diabetes. Hua Medicine is committed to improving patient outcomes and quality of life by leveraging cutting-edge science and technology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

13 Patents

#183 in Shanghai

#1,941 in China

#43,644 in the World

Shanghai, China

Hua Medicine (shanghai) Ltd.

Forward Citations = 5

15 inventors:

Li Chen (13 out of 114 patents)

Yongguo Li (7 out of 8 patents)

Gaosen Wang (6 out of 6 patents)

4. Huisheng Gao (4 out of 4 patents)

5. Shuang Ren (3 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…